Cardiovascular impact of drugs used in the treatment of diabetes

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

The International Diabetes Federation predicts that by 2035 10% of the population of the world will have been diagnosed with diabetes, raising serious concerns over the resulting elevated morbidity and mortality as well as the impact on health care budgets. It is also well recognized that cardiovascular disease is the primary cause of the high morbidity and mortality associated with diabetes, raising the concern that appropriate drug therapy should not only correct metabolic dysfunction, but also protect the cardiovascular system from the effects of, in particular, the epigenetic changes that result from hyperglycaemia. A number of new classes of drugs for the treatment of diabetes have been introduced in the past decade, providing the opportunity to optimize treatment; however, comparative information of the cardiovascular benefits, or risks, of the newer drugs versus older therapies such as metformin is variable. This review, in addition to summarizing the cellular basis for the therapeutic action of these drugs, addresses the evidence for their cardiovascular benefits and risks. A particular focus is provided on metformin as it is the first choice drug for most patients with type 2 diabetes.

Original languageEnglish
Pages (from-to)245-268
Number of pages24
JournalTherapeutic Advances in Chronic Disease
Volume5
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Cardiovascular Agents
Metformin
Pharmaceutical Preparations
Morbidity
Mortality
Budgets
Therapeutics
Cardiovascular System
Epigenomics
Hyperglycemia
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Delivery of Health Care
Drug Therapy
Population

Keywords

  • Cardiovascular disease
  • Diabetes
  • Endothelial dysfunction
  • Hyperglycaemia
  • Hypoglycaemia
  • Insulin
  • Insulin resistance
  • Metformin
  • Sulfonylureas
  • Thiazolidinediones

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Cardiovascular impact of drugs used in the treatment of diabetes. / Triggle, Christopher; Ding, Hong.

In: Therapeutic Advances in Chronic Disease, Vol. 5, No. 6, 2014, p. 245-268.

Research output: Contribution to journalReview article

@article{872d7a38af3b4aa89740328aabe93c29,
title = "Cardiovascular impact of drugs used in the treatment of diabetes",
abstract = "The International Diabetes Federation predicts that by 2035 10{\%} of the population of the world will have been diagnosed with diabetes, raising serious concerns over the resulting elevated morbidity and mortality as well as the impact on health care budgets. It is also well recognized that cardiovascular disease is the primary cause of the high morbidity and mortality associated with diabetes, raising the concern that appropriate drug therapy should not only correct metabolic dysfunction, but also protect the cardiovascular system from the effects of, in particular, the epigenetic changes that result from hyperglycaemia. A number of new classes of drugs for the treatment of diabetes have been introduced in the past decade, providing the opportunity to optimize treatment; however, comparative information of the cardiovascular benefits, or risks, of the newer drugs versus older therapies such as metformin is variable. This review, in addition to summarizing the cellular basis for the therapeutic action of these drugs, addresses the evidence for their cardiovascular benefits and risks. A particular focus is provided on metformin as it is the first choice drug for most patients with type 2 diabetes.",
keywords = "Cardiovascular disease, Diabetes, Endothelial dysfunction, Hyperglycaemia, Hypoglycaemia, Insulin, Insulin resistance, Metformin, Sulfonylureas, Thiazolidinediones",
author = "Christopher Triggle and Hong Ding",
year = "2014",
doi = "10.1177/2040622314546125",
language = "English",
volume = "5",
pages = "245--268",
journal = "Therapeutic Advances in Chronic Disease",
issn = "2040-6223",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Cardiovascular impact of drugs used in the treatment of diabetes

AU - Triggle, Christopher

AU - Ding, Hong

PY - 2014

Y1 - 2014

N2 - The International Diabetes Federation predicts that by 2035 10% of the population of the world will have been diagnosed with diabetes, raising serious concerns over the resulting elevated morbidity and mortality as well as the impact on health care budgets. It is also well recognized that cardiovascular disease is the primary cause of the high morbidity and mortality associated with diabetes, raising the concern that appropriate drug therapy should not only correct metabolic dysfunction, but also protect the cardiovascular system from the effects of, in particular, the epigenetic changes that result from hyperglycaemia. A number of new classes of drugs for the treatment of diabetes have been introduced in the past decade, providing the opportunity to optimize treatment; however, comparative information of the cardiovascular benefits, or risks, of the newer drugs versus older therapies such as metformin is variable. This review, in addition to summarizing the cellular basis for the therapeutic action of these drugs, addresses the evidence for their cardiovascular benefits and risks. A particular focus is provided on metformin as it is the first choice drug for most patients with type 2 diabetes.

AB - The International Diabetes Federation predicts that by 2035 10% of the population of the world will have been diagnosed with diabetes, raising serious concerns over the resulting elevated morbidity and mortality as well as the impact on health care budgets. It is also well recognized that cardiovascular disease is the primary cause of the high morbidity and mortality associated with diabetes, raising the concern that appropriate drug therapy should not only correct metabolic dysfunction, but also protect the cardiovascular system from the effects of, in particular, the epigenetic changes that result from hyperglycaemia. A number of new classes of drugs for the treatment of diabetes have been introduced in the past decade, providing the opportunity to optimize treatment; however, comparative information of the cardiovascular benefits, or risks, of the newer drugs versus older therapies such as metformin is variable. This review, in addition to summarizing the cellular basis for the therapeutic action of these drugs, addresses the evidence for their cardiovascular benefits and risks. A particular focus is provided on metformin as it is the first choice drug for most patients with type 2 diabetes.

KW - Cardiovascular disease

KW - Diabetes

KW - Endothelial dysfunction

KW - Hyperglycaemia

KW - Hypoglycaemia

KW - Insulin

KW - Insulin resistance

KW - Metformin

KW - Sulfonylureas

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=84910055228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910055228&partnerID=8YFLogxK

U2 - 10.1177/2040622314546125

DO - 10.1177/2040622314546125

M3 - Review article

VL - 5

SP - 245

EP - 268

JO - Therapeutic Advances in Chronic Disease

JF - Therapeutic Advances in Chronic Disease

SN - 2040-6223

IS - 6

ER -